Director John L. LaMattina of Ligand Pharmaceuticals Inc (NASDAQ:LGND) completed a matched set of equity transactions on March 6, 2026, exercising options and subsequently selling the same number of shares.
On that date LaMattina exercised options to purchase 2,161 shares of Ligand common stock at an exercise price of $114.15, representing a total cash outlay of $246,678. Immediately thereafter he sold 2,161 shares at $200.76 per share, generating proceeds of $433,842. Following those moves LaMattina is listed as directly owning 30,724 shares of the company.
The stock was trading near $199.65 at the time of the sale and has risen approximately 90% over the last 12 months, according to the trading figures cited alongside the filing. InvestingPro analysis cited in the filing indicates the shares appear overvalued relative to Fair Value metrics, and the platform makes a Pro Research Report available for LGND and more than 1,400 other U.S. equities for investors seeking deeper valuation context.
Those insider transactions occurred against the backdrop of a strong quarterly performance from Ligand. For the fourth quarter of 2025 the company reported earnings per share of $2.02, well above analyst expectations of $1.49. Quarterly revenue totaled $59.7 million, exceeding the consensus estimate of $55.6 million.
For the full year Ligand reported revenue of $268 million, with core revenue amounting to $240 million. Adjusted earnings per share for the year reached $8.13. The company also reported royalty revenue of $50.5 million for the fourth quarter.
Analysts reacted to the results with positive adjustments to their outlooks. Oppenheimer raised its price target to $277 while maintaining an Outperform rating, citing a favorable view on royalty revenue. Stifel reiterated its Buy rating and maintained a $230 price target following the stronger-than-expected revenue performance. These analyst actions were described in company commentary as reflecting robust financial results and favorable sentiment among sell-side analysts.
The combination of an insider option exercise and immediate sale is a common structuring approach that can crystallize gains while leaving the insider with continued direct ownership in the company. LaMattina's retained holding of 30,724 shares means he remains a direct shareholder after the transactions.
Investors and market participants will note the tension between the company's recent operating beat and the InvestingPro Fair Value assessment that the shares may be overvalued at current market levels. That divergence is part of the broader picture investors must weigh when interpreting insider activity alongside quarterly performance and analyst revisions.